Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LBY004
MIFTS: 35

Labyrinthitis

Categories: Ear diseases, Infectious diseases, Neuronal diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Labyrinthitis

About this section

MalaCards integrated aliases for Labyrinthitis:

Name: Labyrinthitis 12 76 44 15 73
Labyrinthine Disorder 73

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Ear diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1468
ICD10 33 H83.0 H83.09
ICD9CM 35 386.3 386.30
MeSH 44 D007762
SNOMED-CT 68 23919004
Sources

Summaries for Labyrinthitis

About this section
Disease Ontology : 12 An otitis interna which involves inflammation of the labyrinths.

MalaCards based summary : Labyrinthitis, also known as labyrinthine disorder, is related to purulent labyrinthitis and focal labyrinthitis, and has symptoms including vertigo and earache. An important gene associated with Labyrinthitis is CRLF1 (Cytokine Receptor Like Factor 1). The drugs Glucosamine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Labyrinthitis, also known as vestibular neuritis, is the inflammation of the inner ear. It results in a... more...

Sources

Related Diseases for Labyrinthitis

About this section

Diseases in the Labyrinthitis family:

Viral Labyrinthitis

Diseases related to Labyrinthitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 purulent labyrinthitis 12.5
2 focal labyrinthitis 12.4
3 viral labyrinthitis 12.4
4 toxic labyrinthitis 12.4
5 serous labyrinthitis 12.2
6 bilateral hyperactive labyrinth 12.0
7 unilateral hyperactive labyrinth 12.0
8 bilateral hypoactive labyrinth 12.0
9 unilateral hypoactive labyrinth 12.0
10 meniere disease 11.4
11 inner ear disease 11.4
12 vestibular neuronitis 11.0
13 cochlear disease 11.0
14 meningitis 10.5
15 otitis media 10.5
16 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
17 sensorineural hearing loss 10.2
18 suppurative otitis media 10.2
19 vertigo, benign recurrent 10.1
20 benign paroxysmal positional nystagmus 10.1
21 mastoiditis 10.1
22 mumps 10.1
23 otosclerosis 10.1
24 sudden sensorineural hearing loss 10.1
25 pneumococcal meningitis 10.0
26 thrombosis 9.9
27 acoustic neuroma 9.9
28 dementia 9.9
29 facial paralysis 9.9
30 chronic purulent otitis media 9.9
31 neurilemmoma 9.9
32 herpes simplex 9.9
33 autoimmune inner ear disease 9.9
34 congenital cytomegalovirus 9.9
35 headache 9.9
36 popliteal pterygium syndrome 9.8
37 lipomatosis, multiple 9.8
38 motion sickness 9.8
39 osteoporosis 9.8
40 otosclerosis 1 9.8
41 raynaud disease 9.8
42 torticollis 9.8
43 osteoid osteoma 9.8
44 retinitis pigmentosa-deafness syndrome 9.8
45 macular degeneration, age-related, 1 9.8
46 anorexia nervosa 9.8
47 malaria 9.8
48 kawasaki disease 9.8
49 polyarteritis nodosa, childhood-onset 9.8
50 ulcerative colitis 9.8

Comorbidity relations with Labyrinthitis via Phenotypic Disease Network (PDN): (show all 22)


Anxiety Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebrovascular Disease Chronic Myocardial Ischemia
Esophagitis Generalized Atherosclerosis
Hypertension, Essential Hypothyroidism
Inner Ear Disease Intermediate Coronary Syndrome
Ischemic Heart Disease Meniere Disease
Otitis Media Pathologic Nystagmus
Peripheral Vertigo Transient Cerebral Ischemia
Vertebral Artery Insufficiency Vertigo, Benign Recurrent
Vestibular Nystagmus Viral Labyrinthitis

Graphical network of the top 20 diseases related to Labyrinthitis:



Diseases related to Labyrinthitis
Sources

Symptoms & Phenotypes for Labyrinthitis

About this section

UMLS symptoms related to Labyrinthitis:


vertigo, earache

GenomeRNAi Phenotypes related to Labyrinthitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.5 POU3F4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.5 POU3F4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.5 IGBP1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.5 POU3F4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.5 IGBP1 NCS1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.5 NCS1 POU3F4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.5 POU3F4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.5 IGBP1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.5 IGBP1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.5 NCS1
Sources

Drugs & Therapeutics for Labyrinthitis

About this section

Drugs for Labyrinthitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
2
Histamine Approved, Investigational Phase 4,Phase 3,Not Applicable 51-45-6, 75614-87-8 774
3
Dimenhydrinate Approved Phase 4,Phase 3 523-87-5 441281
4
Betahistine Approved, Investigational Phase 4,Not Applicable 5638-76-6 2366
5
Caffeine Approved Phase 4 58-08-2 2519
6 Piracetam Approved, Investigational Phase 4 7491-74-9
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
10
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
11
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
12
Glycerol Approved, Investigational Phase 4 56-81-5 753
13
Thymol Approved Phase 4 89-83-8 6989
14
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
15
Ethanol Approved Phase 4 64-17-5 702
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
20
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
23
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
26
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28 Tocotrienol Investigational Phase 4 6829-55-6
29
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3 2920-86-7
30 Anticoagulants Phase 4
31 Hypoglycemic Agents Phase 4
32 Fibrinolytic Agents Phase 4
33 Antimetabolites Phase 4,Phase 3
34 Lipid Regulating Agents Phase 4
35 Glucuronyl glucosamine glycan sulfate Phase 4
36 Hypolipidemic Agents Phase 4
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38
Histamine Phosphate Phase 4,Phase 3,Not Applicable 51-74-1 65513
39 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Histamine Antagonists Phase 4,Phase 3,Not Applicable
42 Histamine H1 Antagonists Phase 4,Phase 3,Not Applicable
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 2
46 Vasodilator Agents Phase 4,Phase 1,Not Applicable
47 Sildenafil Citrate Phase 4 171599-83-0
48 Phosphodiesterase Inhibitors Phase 4,Not Applicable
49 Citrate Phase 4
50 Phosphodiesterase 5 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
2 Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Completed NCT02718846 Phase 4 Meniace;Isobide
3 Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
5 Sildenafil For Meniere's Disease Completed NCT00145483 Phase 4 Sildenafil
6 Effect of Caffeine Intake in Vestibular Function Completed NCT02825199 Phase 4
7 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Completed NCT01890538 Phase 4 Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
8 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4 Dimenhydrinate;Metoclopramide
9 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV Completed NCT02031692 Phase 4 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
10 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
11 Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
12 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Recruiting NCT02530931 Phase 4 Gadolinium
13 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4 Gadoteric acid
14 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
15 A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4 Merislon
16 Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin Unknown status NCT02112578 Phase 3 Meclizine;Dimenhydrinate
17 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
18 Conventional Versus Virtual Reality Based Vestibular Rehabilitation Completed NCT01442623 Phase 2, Phase 3
19 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
20 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
21 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
22 Study of Lamotrigine to Treat Ménière's Disease Completed NCT02158585 Phase 3 Lamotrigine;Placebo
23 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
24 Promethazine vs. Lorazepam for Treatment of Vertigo Completed NCT01827293 Phase 3 Promethazine;Lorazepam
25 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
26 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
27 Canalith Repositioning Procedure for BPPV in Primary Care Completed NCT00182273 Phase 3
28 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
29 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Recruiting NCT03664674 Phase 3 OTO-104;Placebo
30 Rizatriptan for Episodic Dizziness in Vestibular Migraine Recruiting NCT02447991 Phase 2, Phase 3 Rizatriptan;Placebo
31 Caroverin and Inner Ear Diseases Suspended NCT01174979 Phase 3 Caroverin
32 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
33 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
34 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
35 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
36 Famvir for Treatment of Hearing in Unilateral Meniere's Disease Terminated NCT01526408 Phase 3 Famciclovir;Placebo
37 Latanoprost for the Treatment of Menière's Disease Unknown status NCT01973114 Phase 2 Latanoprost
38 Visual Feedback Goggle for Positional Vertigo Treatment Unknown status NCT00729885 Phase 1, Phase 2
39 Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy Unknown status NCT02247648 Phase 2 tramadol;Placebo
40 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
41 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
42 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
43 A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom Completed NCT02265393 Phase 2 OTO-104;Placebo
44 OTO-104 for the Treatment of Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
45 A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Completed NCT02299804 Phase 2 Levophencynonate Hydrochloric;Placebo
46 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
47 Effect of V0251 in Acute Vertigo Completed NCT01583738 Phase 2 V0251;placebo
48 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
49 Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00000359 Phase 2
50 A Trial of Booklet Based Self Management of Dizziness Completed NCT00732797 Phase 2

Search NIH Clinical Center for Labyrinthitis

Cochrane evidence based reviews: labyrinthitis

Sources

Genetic Tests for Labyrinthitis

About this section
Sources

Anatomical Context for Labyrinthitis

About this section

MalaCards organs/tissues related to Labyrinthitis:

41
Eye, Bone, Brain, Testes, Endothelial, Bone Marrow
Sources

Publications for Labyrinthitis

About this section

Articles related to Labyrinthitis:

(show top 50) (show all 215)
# Title Authors Year
1
Labyrinthitis Ossificans in a Cynomolgus Macaque (Macaca fascicularis). ( 29650059 )
2018
2
Differentiation Between Intralabyrinthine Schwannoma and Contrast-enhancing Labyrinthitis on MRI: Quantitative Analysis of Signal Intensity Characteristics. ( 30020263 )
2018
3
Gradenigo's Syndrome and Labyrinthitis: Conservative versus Surgical Treatment. ( 30155332 )
2018
4
Facial Nerve Stimulation Patterns Associated With Cochlear Implantation in Labyrinthitis Ossificans. ( 30444844 )
2018
5
"Emergency" Cochlear Implantation in Labyrinthitis Ossificans Secondary to Polyarteritis Nodosa: How to Face a Rare Entity. ( 30541729 )
2018
6
Cochlear Implant Associated Labyrinthitis: A Previously Unrecognized Phenomenon With a Distinct Clinical and Electrophysiological Impedance Pattern. ( 29065095 )
2017
7
Kawasaki Disease and Labyrinthitis: An Underdiagnosed Complication. ( 28417110 )
2017
8
Deterioration of Vestibular Cells in Labyrinthitis. ( 27881797 )
2017
9
Nystagmus in patients with unilateral acute otitis media complicated by serous labyrinthitis. ( 26797398 )
2016
10
Quantitative Assessment of Cochlear Histopathologic Findings in Patients With Suppurative Labyrinthitis. ( 26987015 )
2016
11
Labyrinthitis ossificans after meningitis: Superiority of high-resolution magnetic resonance imaging in demonstration of disease extent compared to high-resolution computed tomography. ( 27114680 )
2016
12
Pathologic Findings of the Cochlea in Labyrinthitis Ossificans Associated with the Round Window Membrane. ( 27221575 )
2016
13
Suppurative labyrinthitis associated with otitis media: 26 years' experience. ( 26718959 )
2016
14
Pneumolabyrinth with Labyrinthitis as the Suspected Cause. ( 27115607 )
2016
15
Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study. ( 26954857 )
2016
16
Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )
2015
17
Rapidly Destructive Autoimmune Labyrinthitis Associated With Ulcerative Colitis. ( 26385058 )
2015
18
The Impact of Postmeningitic Labyrinthitis Ossificans on Speech Performance After Pediatric Cochlear Implantation. ( 26536413 )
2015
19
Labyrinthitis Ossificans: On the Mechanism of Perilabyrinthine Bone Remodeling. ( 25757630 )
2015
20
Refractory Positional Vertigo With Apogeotropic Horizontal Nystagmus After Labyrinthitis: Surgical Treatment and Identification of Dysmorphic Ampullae. ( 26208126 )
2015
21
The incidence of tympanogenic labyrinthitis ossificans. ( 25075947 )
2014
22
Bilateral sensorineural hearing loss and labyrinthitis ossificans secondary to neurosarcoidosis. ( 25189997 )
2014
23
Clinical outcome after cochlear implantation in patients with unilateral hearing loss due to labyrinthitis ossificans. ( 23921941 )
2013
24
High-resolution 3-D T2-weighted imaging in the diagnosis of labyrinthitis ossificans: emphasis on subtle cochlear involvement. ( 23843131 )
2013
25
Labyrinthitis ossificans in a cochlear implant patient with Usher syndrome. ( 23455060 )
2013
26
Tuberculous otitis media with facial paralysis combined with labyrinthitis. ( 24653900 )
2013
27
End-stage labyrinthitis with extensive erosion of the bony labyrinth. ( 22377652 )
2012
28
Acute labyrinthitis secondary to aural tick infestation. ( 23077807 )
2012
29
Effect of Ginkgo biloba extract on endotoxin-induced labyrinthitis. ( 21592590 )
2011
30
Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. ( 21526906 )
2011
31
Radiology quiz case 2. Labyrinthitis ossificans secondary to suppurative labyrinthitis. ( 21422319 )
2011
32
Deafness due to haemorrhagic labyrinthitis and a review of relapses in Streptococcus suis meningitis. ( 20358139 )
2010
33
Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )
2010
34
Labyrinthitis ossificans. ( 19300296 )
2009
35
Labyrinthitis ossificans in a child with sickle cell disease: CT and MRI findings. ( 19415252 )
2009
36
Posttraumatic labyrinthitis ossificans with perilymphatic fistulization. ( 19862674 )
2009
37
Labyrinthitis ossificans: how accurate is MRI in predicting cochlear obstruction? ( 19393413 )
2009
38
Serous labyrinthitis as a manifestation of cat scratch disease: a case report. ( 20519021 )
2009
39
Meningitis resulting in hearing loss and labyrinthitis ossificans - does the causative organism matter? ( 18246540 )
2008
40
Induction of cytomegalovirus-infected labyrinthitis in newborn mice by lipopolysaccharide: a model for hearing loss in congenital CMV infection. ( 18475257 )
2008
41
Nitrogen and oxygen molecules in meningitis-associated labyrinthitis and hearing impairment. ( 18084715 )
2008
42
Labyrinthitis related to Wegener granulomatosis: magnetic resonance imaging findings. ( 18097336 )
2008
43
Progressive cochleo-vestibular labyrinthitis. ( 17633668 )
2007
44
Advancement in post-meningitic lateral semicircular canal labyrinthitis ossificans. ( 17123454 )
2007
45
Otogenic cerebellar abscess due to purulent labyrinthitis and defect of the superior semicircular canal and its propagation through the endolymphatic sac. ( 17372752 )
2007
46
Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. ( 17208485 )
2007
47
Radiology quiz case 1. Labyrinthitis ossificans (LO)-stage of fibrosis. ( 17372090 )
2007
48
AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis. ( 18322422 )
2007
49
Otitis interna (labyrinthitis) associated with Salmonella enterica arizonae in turkey poults. ( 16617998 )
2006
50
TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. ( 16547758 )
2006
Sources

Variations for Labyrinthitis

About this section
Sources

Expression for Labyrinthitis

About this section
Search GEO for disease gene expression data for Labyrinthitis.
Sources

Pathways for Labyrinthitis

About this section
Sources

GO Terms for Labyrinthitis

About this section
Sources

Sources for Labyrinthitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....